#Nephtwitter
🚨 Late Breaking Research #2
Fantastic results presented by Matthew Renfrow! 🔥
🔛 The bidirectional influence between Gd-IgA1 and kidney outcomes!

tobias-b-huber.bsky.social CureGN
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
November 15, 2026 at 5:39 PM
🚨 Late Breaking Research #3
🌟 Fantastic talk by Abigail Smith!
👉 The promising role of eGFR and proteinuria as surrogate markers in APOL1 kidney disease

tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
November 15, 2026 at 5:50 PM
🔥 Meeting practical needs and optimizing trial design in #GlomerularDisease by Hiddo Heerspink!
Which trial is best for which disease and context? 🔎

tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #ClinicalTrials #NephTwitter #Nephrology
November 14, 2026 at 3:56 PM
Suceena Alexander disruptive presentation 💥
🔜 Multi-arm trials and trial platforms are much needed in #GlomerularDisease!

🐙 Should we call them octopus or even 'podocyte' trials?

tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #ClinicalTrials #NephTwitter #Nephrology
November 14, 2026 at 3:45 PM
1/
Hey #Nephtwitter!
Welcome to a 🆕 #tweetorial #xtorial brought to you by @KIReports
🦠 Today, we're exploring BK polyomavirus-specific immunity and viral clearance after kidney transplantation. VA by @mdabdulqader83.bsky.social
November 10, 2026 at 6:02 PM
🌟 Fantastic talk by Sean Barbour about the use of risk prediction tools in clinical trials!
Visit GNpredict.com to access evidence-based prediction tools 💥

tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
November 14, 2026 at 3:32 PM
🚨 Emerging biomarkers session #4
Timothy Niewold brilliantly uncovering current trials and emerging therapis targeting innate immune pathways in #GlomerularDisease

#CTS2026 #ISGD #ClinicalTrials #NephTwitter #Nephrology
tobias-b-huber.bsky.social
November 13, 2026 at 11:00 PM
🚨 Emerging biomarkers session #6
Jonathan Hogan finishing this fantastic table with cellular therapy and bispecific antibodies for #GlomerularDisease 🔥
Impressive results, distinct toxicities, potential cure? 🔎

#CTS2026 #ISGD #ClinicalTrials #NephTwitter #Nephrology
tobias-b-huber.bsky.so
November 13, 2026 at 11:29 PM
🚨 Emerging biomarkers session #3
Alexander Duncan revolutionizing talk about targeting suPAR with the new monoclonal antibody WAL0921 💫
Promising early clinical results! 🚀🔜

#CTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
tobias-b-huber.bsky.social
November 13, 2026 at 10:50 PM
🚨 Emerging biomarkers session #1
Laura Mariani brilliantly discussed how biomarkers can be used as endpoints for clinical trials and their regulatory framework 🔥
Exciting times ahead! 🔜

#CTS2026 #ISGD #GlomerularDisease #ClinicalTrials #NephTwitter #Nephrology
tobias-b-huber.bsky.social
November 13, 2026 at 10:33 PM
🚨 ISGD announces the first-of-its-kind partnership!
ISGD 🤝 Qualified Health
The first AI-enabled research network!

The future is here.
We are the doers.

tobias-b-huber.bsky.social utmbhealth.bsky.social
#CTS2026 #ISGD #GlomerularDisease #ClinicalTrials #AI #NephTwitter #Nephrology
November 13, 2026 at 6:25 PM
2/
Our author is @ManoleaA (nephrology resident)
Our topic: Early BK Polyomavirus–Specific Immunity and Viral Clearance
🔗https://www.sciencedirect.com/science/article/pii/S2468024926032961
#MedTwitter #nephtwitter @ISNkidneycare #XTwitter
November 10, 2026 at 6:02 PM
🎧 This Week in Nephrology — the week's key papers in a free ~10-min AI briefing.
🔬 Editor's Pick from New England Journal of Medicine

Listen / Read or Share with a colleague 👇
audioscholar.cc/feed/nephrology?w=2026-W43

#NephTwitter #FOAMed
Nephrology Weekly — AudioScholar
A ~10-minute, PubMed-sourced audio briefing of the week's nephrology literature. Free, every week.
audioscholar.cc
October 21, 2026 at 6:50 AM
1/ Tweetorial Alert 🚨
🆕 Hey #NephTwitter!
Welcome to a new #tweetorial brought to you by @KIReports!
🫘 Can artificial intelligence improve risk prediction in IgA nephropathy?
🔬 Let's explore how pathomics could reshape kidney biopsy interpretation!
October 17, 2026 at 12:09 PM
🧵Tweetorial Alert 🧵
1/
Hey #NephTwitter!
Welcome to a 🆕 #tweetorial #xtorial brought to you by @KIReports @divyaveerssneph.bsky.social
Redirecting
doi.org
October 16, 2026 at 11:49 AM
2/
Our author is @divyaveerssneph.bsky.social

Our topic: Characterization of Patient-Reported Loin Pain in IgAN
doi.org/10.1016/j.ek...

#MedTwitter #nephtwitter @ISNkidneycare #XTwitter
@divyaveerssneph.bsky.social
October 16, 2026 at 11:49 AM
1/10
#NephJC #TenPostNephJC.
#NephTwitter
Patient outcomes are better with transplant vs dialysis.
Is this always true?
What about high-risk donors (expanded criteria donor-ECD) or recipients (elderly with DM or CVD)?
Read the article 👇
link to article on pubmed.ncbi.nlm.nih.gov/42759976/
October 14, 2026 at 1:00 AM
October 12, 2026 at 3:04 PM
Huge thanks to our amazing faculty for their time and expertise! 🙌 Next stop: Clinical Trials Bootcamp in Mar del Plata, Argentina! 🇦🇷 Stay tuned. 3/3
#ISGD #ClinicalTrials #Nephrology #GlomerularDisease #ESPN2026 #PediatricNephrology #CTB #nephtwitter
October 8, 2026 at 4:32 PM
October 5, 2026 at 5:06 PM
1/ 🧵Tweetorial Alert 🧵Hey, #NephTwitter
Welcome to a 🆕 #tweetorial #xtorial brought to you by @KIReports
October 5, 2026 at 2:45 PM
2/ Our author is Anca-Elena Stefan (@ancast13.bsky.social) (Nephrology specialist from Romania)
Our topic: 10-year trends in Heart Failure Among Patients with Dialysis and Nondialysis CKD
🔗 www.kireports.org/article/S246...
#MedTwitter #nephtwitter @ISNkidneycare #XTwitter
October 5, 2026 at 2:45 PM
🎧 This Week in Nephrology — the week's key papers in a free ~10-min AI briefing.
🔬 Editor's Pick from Clinical Journal of the American Society of Nephrology

Listen / Read or Share with a colleague 👇
audioscholar.cc/feed/nephrology

#NephTwitter #FOAMed
Nephrology Weekly — AudioScholar
A ~10-minute, PubMed-sourced audio briefing of the week's nephrology literature. Free, every week.
audioscholar.cc
October 2, 2026 at 10:39 AM
7/10
Question 2
#NephJC #NephTwitter
Q: Can MCD & FSGS receive similar steroid taper regimens?
A: Probably not! We need a more adequately powered trial to answer this, especially with FSGS which remains more treatment resistant & steroid resistance may be disease defining
September 30, 2026 at 1:27 AM